Efficacy and safety of antifibrotic agents for interstitial lung disease associated with rheumatoid arthritis

Efficacy and safety of antifibrotic agents for interstitial lung disease associated with rheumatoid arthritis - Efficacy and safety of antifibrotic agents for interstitial lung disease associated with rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052195

Enrollment

500

Registered

2023-10-01

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the following criteria will be considered: 1. patients who meet the 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis 2. patients with interstitial pneumonia on chest x-ray or chest CT

Exclusion criteria

Exclusion criteria: Patients who are in conflict with any of the following will not be included in this study: 1. patients complicated with collagen diseases other than RA 2. patients with a hospital history of less than 6 months

Design outcomes

Primary

Measure	Time frame
To collect clinical information from patients registered in the Yokohama City University Rheumatic disease Database (Y-CURD) and patients with RA-ILD attending the Kanagawa Cardiovascular and Respiratory Disease Center. 1. Lung cancer complication rate 2. ILD relapse rate 3. Overall survival We evaluate these outcomes with/without antifibrotic agents.	—

Countries

Japan

Contacts

Public ContactKaoru Minegishi

Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation

kaoru_t@yokohama-cu.ac.jp045-787-2630

Outcome results